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Abstract
Background: Exposure to toxins/chemicals is considered to be a significant risk factor in the
pathogenesis of Parkinson's disease (PD); one putative chemical is the naturally occurring herbicide
rotenone that is now used widely in establishing PD models. We, and others, have shown that
chronic low dose rotenone treatment induces excessive accumulation of Reactive Oxygen Species
(ROS), inclusion body formation and apoptosis in dopaminergic neurons of animal and human
origin. Some studies have also suggested that microglia enhance the rotenone induced
neurotoxicity. While the effects of rotenone on neurons are well established, there is little or no
information available on the effect of rotenone on microglial cells, and especially cells of human
origin. The aim of the present study was to investigate the effects of chronic low dose rotenone
treatment on human microglial CHME-5 cells.
Methods: We have shown previously that rotenone induced inclusion body formation in human
dopaminergic SH-SY5Y cells and therefore used these cells as a control for inclusion body
formation in this study. SH-SY5Y and CHME-5 cells were treated with 5 nM rotenone for four
weeks. At the end of week 4, both cell types were analysed for the presence of inclusion bodies,
superoxide dismutases and cell activation (only in CHME-5 cells) using Haematoxylin and Eosin
staining, immunocytochemical and western blotting methods. Levels of active caspases and ROS
(both extra and intra cellular) were measured using biochemical methods.
Conclusion: The results suggest that chronic low dose rotenone treatment activates human
microglia (cell line) in a manner similar to microglia of animal origin as shown by others. However
human microglia release excessive amounts of ROS extracellularly, do not show excessive amounts
of intracellular ROS and active caspases and most importantly do not show any protein aggregation
or inclusion body formation. Human microglia appear to be resistant to rotenone (chronic, low
dose) induced damage.
Background
Parkinson's disease (PD) is the most prevalent neurode-
generative movement disorder [1]; genetic mutations are
found in rare cases of familial PD, however more than
90% of cases are sporadic without known cause [2]. The
role of microglia, the resident immune cells of the Central
Nervous System (CNS), has rapidly gained attention from
researchers interested in understanding the pathogenesis
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of PD. Chronic microglial activation, subsequent neu-
roinflammation and accumulation of Reactive Oxygen
Species (ROS) are now accepted as significant contribu-
tors in the disease progression [3,4]. The importance of
the role played by microglia in inducing neuroinflamma-
tion in PD is highlighted by the fact that the substantia
nigra, a region that shows extensive degeneration of
dopaminergic neurons in PD, is also the region most
densely populated with microglial cells [5,6]. Dopaminer-
gic neurons also show a unique vulnerability to the factors
released by activated microglia. It is therefore important
to fully understand the interaction between microglia and
neurons and the precise mechanisms by which microglia
influence dopaminergic neuronal cell loss through the use
of in-vitro and in-vivo models of PD.
Neurodegenerative diseases are difficult to model. A
number of epidemiological studies have identified a
strong correlation between exposure to pesticides and
increased incidence of PD [7-11], suggesting pesticides as
the accelerators/promoters of PD. Some of the pesticides
in question were found to inhibit complex I enzyme activ-
ity [8,12]. Based on these experimental and clinical find-
ings, PD was the first neurological disease to be modelled.
Chemicals such as reserpine, methamphetamine, 6-
hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahy-
droxypyridine (MPTP), paraquat and rotenone have all
been used to make PD models [13,14]. Studies by Betar-
bet and colleagues [12,15,16], reported that chronic treat-
ment with the herbicide rotenone led to selective
destruction of nigrostriatal dopaminergic neurons, forma-
tion of cytoplasmic inclusions in nigral neurons and
induction of hypokinesia and rigidity in rats. These stud-
ies have drawn a lot of attention highlighting rotenone's
potential use as a model for toxin-induced Parkinsonism.
Rotenone is commonly used as a natural pesticide, an
insecticide and to kill 'nuisance' fish in lakes. Rotenone is
a lipophilic compound and can easily cross the blood-
brain barrier [13,14]. Though chronic exposure to low
doses of rotenone results in uniform inhibition of com-
plex I throughout the brain, rotenone has been shown to
induce selective degeneration of the nigrostriatal pathway
[12]. Although some researchers [17,18] have reported
non-specific central nervous system and systemic toxicity
in rats upon rotenone treatment, recently Cannon et al.,
(2009) [2] have reproduced consistently many features of
PD in rats following chronic intraparitoneal administra-
tion of rotenone. Features include systemic mitochondrial
impairment, oxidative damage, microglial activation,
selective nigrostriatal dopaminergic degeneration, L-Dopa
responsive motor deficit, gastrointestinal deficit and α-
synuclein and ubiquitin positive lewy body-like inclusion
bodies within TH-positive neurons. Rotenone has also
been used successfully to reproduce PD characteristics in
in-vitro slice culture models [19], primary cultures [20]
and recently we have shown accumulation of α-synuclein
positive inclusions within four weeks of chronic low dose
treatment of SH-SY5Y dopaminergic cells of human origin
[21].
Microglial activation and neuroinflammation have been
identified as important contributors in human PD patho-
genesis, and several rotenone models have demonstrated
microglial activation in the striatum of the treated animals
[2,12]. Recent studies have reported that microglia con-
tribute significantly in mediating and potentiating the
neurodegenerative effects of rotenone [22,23]. There is
however, very little or no information available on the
direct effects of rotenone on microglial cells. Some
authors have reported microglial activation upon roten-
one treatment in the microglia of rodent origin [2,12].
There are however some important differences between
human and rodent microglia in the way they release
superoxide in response to the same activating agents. Fur-
thermore, and in contrast to rodent microglia, human
microglia are thought to produce very little or no induci-
ble nitric oxide synthase (iNOS) [24,25]. In this study, we
report the direct effects of chronic low dose rotenone
treatment on human microglial cells.
Results
Chronic low dose rotenone treatment does not induce 
intracellular inclusion formation in human microglial cells
We have reported previously the appearance of cytoplas-
mic  α-synuclein positive inclusion bodies in human
dopaminergic SH-SY5Y cells [21]. In the present study we
investigated the effects of chronic low dose rotenone treat-
ment on the human microglial cells, using SH-SY5Y cells
as a control for the induction of inclusion bodies. CHME-
5 and SH-SY5Y cells were treated in the same way and
examined for the presence of inclusion bodies at the end
of four weeks using H & E staining and immunocyto-
chemical staining for α-synuclein and ubiquitin. As
reported earlier by us [21], the inclusion bodies were seen
in SH-SY5Y cells within 4 weeks of rotenone treatment;
these inclusion bodies were eosinophilic and positive for
both α-synuclein and ubiquitin (Figure 1A, C and 1E).
Interestingly no inclusion bodies were seen in the human
microglial CHME-5 cells (Figure 1B, D and 1F) indicating
that the CHME-5 cells are more resistant to inclusion for-
mation and to rotenone induced damage. No inclusion
bodies were seen in the control group of both cell types
(data not shown).
Rotenone treatment activates microglia
Glut-5 band (55 kDa) was not detected in untreated con-
trol CHME-5 cells in the amount (15 μg) of total protein
loaded in this study (Figure 2A). However rotenone
treated CHME-5 cells showed a significant increase in theMolecular Neurodegeneration 2009, 4:55 http://www.molecularneurodegeneration.com/content/4/1/55
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Detection of inclusion bodies Figure 1
Detection of inclusion bodies. Representative photomicrographs showing H & E staining (A and B), α-synuclein staining (C 
& D) and ubiquitin staining (E and F) in the two cell types (SH-SY5Y and CHME-5) collected at the end of 4 week's of rotenone 
(5 nm) treatment. SH-SY5Y cells showed eosinophilic (A, arrow head), α-synuclein positive (C, arrow head) and ubiquitin pos-
itive (E, arrow head) inclusion bodies. No inclusion bodies were seen in human microglial CHME-5 cells (B, D and F). Results 
shown are representative of three independent experiments. Scale bar: 50 μm.Molecular Neurodegeneration 2009, 4:55 http://www.molecularneurodegeneration.com/content/4/1/55
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levels of Glut-5 proteins at the end of week four (Figure 2A
and 2B). Glut-5 is a glucose transporter, specifically
expressed in resting and reactive microglia with its expres-
sion increased upon activation [26,27]. Activation of
microglia upon rotenone treatment was also confirmed
by CR3/43 immunostaining; CR3/43 is a marker for acti-
vated microglia. CR3/43 immunostaining per cell was
increased dramatically in rotenone treated cells compared
to controls (Figure 2C). A relative 2.27 fold increase in
Glut-5 levels and a dramatic increase in intracellular CR3/
43 immunostaining in rotenone treated cells compared to
controls suggest increased microglial activation in the
rotenone treated group.
Microglia do not accumulate intracellular ROS upon 
treatment with rotenone
Reactive oxygen Species (ROS) were measured using the
DHE assay for intracellular and the Acridan Lumigen PS-3
assay for extracellular ROS in both cell types (CHME-5
and SH-SY5Y) at the end of 4 week's rotenone treatment.
The amount of ROS accumulated within cells was not sig-
nificantly different in the CHME-5 cells treated with low
dose rotenone compared to untreated controls (Figure 3A
and 3B), however, as reported previously by us [21],
rotenone treated SH-SY5Y cells showed a 2 fold significant
increase in intracellular ROS compared to the untreated
controls (Figure 3A and 3B). Interestingly, the CHME-5
cells release excessive amounts of ROS extracellularly, as
detected in the culture medium, while the levels of extra-
cellular ROS in the culture media from rotenone treated
and untreated SH-SY5Y cells were approximately the same
(Figure 3C). These results suggest that, despite microglial
activation upon rotenone treatment, ROS are not accumu-
lated in excessive amounts within microglial cells. These
cells release large amounts of ROS extracellularly into the
culture media. In contrast, rotenone treated SH-SY5Y cells
accumulate excessive ROS (generated as a result of roten-
one treatment) within cells.
Incubation of the culture media from rotenone treated
cells with 100 μM Ascorbic acid (Vitamin C) reduced the
chemiluminescence dramatically whereas incubation of
the culture media from rotenone treated CHME-5 cells
with NuPAGE antioxidant completely inhibited the
chemiluninescence in the Acridan Ps-3 assay (Figure 3D)
suggesting that the chemiluminescence generated in the
Acridan PS-3 assay was specifically due to the presence of
ROS in the culture media. Vitamin C incubation did not
completely inhibit the chemiluminescence, suggesting
that the ROS other than superoxide were also present.
Superoxide appears to be the main ROS present as
indicted by the dramatic reduction in the light intensity
after incubation with Vitamin C (Figure 3D).
Glut-5 levels in microglial CHME-5 cells Figure 2
Glut-5 levels in microglial CHME-5 cells. Figure 2A: 
Representative immunoblot showing the levels of Glut-5 pro-
tein (55 kDa, first row) in the cell lysates collected at the end 
of week 4 from the control and rotenone (5 nm) treated 
CHME-5 cells. β-actin (42 kDa, second row) was used as an 
internal loading control. Figure 2B: Histogram showing rela-
tive semi-quantitation of Glut-5 levels. Glut-5 levels were 
normalised against the β-actin levels in each well and 
expressed in densitometric units. P (p = 0.039) value indi-
cates a significant difference in Glut-5 levels between control 
and rotenone treated groups. Each column represents the 
mean and standard deviation from three independent experi-
ments. Figure 2C: Representative photomicrographs show-
ing immunostaining of CR3/43 (HLA DR/DP/DQ) in control 
and rotenone treated CHME-5 cells at the end of week 4 of 
the treatment period. CR3/43 staining is dramatically 
increased in rotenone treated cells as visualised by the green 
fluorescence. Scale bar: 50 μm.Molecular Neurodegeneration 2009, 4:55 http://www.molecularneurodegeneration.com/content/4/1/55
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Detection of Reactive Oxygen Species (ROS) Figure 3
Detection of Reactive Oxygen Species (ROS). Figure 3A: Detection of ROS using DHE fluorescent dye in CHME-5 and 
SH-SY5Y cells from the two treatment groups (DMSO control and 5 nm rotenone) at the end of week 4. Hoechst 33258 stain 
(blue) was used to identify the nucleus of cells. The fluorescent intensity of the red dots in the nucleus indicates the relative 
levels of ROS present in the cell. Scale bar: 20 μm. Figure 3B: Histogram showing the levels of ROS in each of the treatment 
groups in both cell types (CHME-5 and SH-SY5Y) at the end of week 4. The levels are expressed in densitometric units. P (*p 
> 0.05) value indicates that there was no significant difference in ROS levels between the control and rotenone treated CHME-
5 cells. However rotenone treated SH-SY5Y cells showed a significant (**P < 0.001) two fold increase in the intracellular ROS 
levels compared to the untreated controls. Each column represents the mean and standard deviation from three independent 
experiments Figure 3C: Histogram representing the extracellular levels of ROS using the Acridan Lumigen PS-3 assay in the 
medium collected from both treatment groups (DMSO control and 5 nm rotenone) and both cell types (CHME-5 and SH-
SY5Y) at the end of week 4. The levels are expressed in light intensity units. CHME-5 cells released significantly higher (*p < 
0.001) levels of ROS in the medium compared to controls, while the extracellular release of ROS in the medium from roten-
one treated and untreated SH-SY5Y cells was not significantly different (**P > 0.05). Each column represents the mean and 
standard deviation from three independent experiments. Figure 3D: Image showing the effects of antioxidants on chemilumi-
nescence in the Acridan Lumigen PS-3 assay. Chemiluminescent signals were captured using Fujifilm Luminescent Image Ana-
lyzer (Dots) and light intensity units were recorded using the BioTek Synergy 2 plate reader (bar graph). a: culture medium 
from CHME-5 cells treated with 5 nm rotenone for 4 weeks, b: culture medium (as in a) incubated with 100 μM ascorbic acid 
(vitamin C) for 5 minutes, c: culture medium (as in a) incubated with NuPAGE antioxidant (1:500 diluted). The dramatic reduc-
tion of chemiluminescence in the media incubated with antioxidants indicates that the chemiluminescence in Acridan PS-3 assay 
is ROS specific.Molecular Neurodegeneration 2009, 4:55 http://www.molecularneurodegeneration.com/content/4/1/55
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Chronic low dose rotenone treatment does not induce 
apoptosis in human microglia
FLICA assay was performed in both cell types at the end of
the four week's rotenone treatment. SH-SY5Y cells were
used as a positive control for apoptosis and to confirm
FLICA assay's specificity. FLICA reagent SR-VAD-FMK
binds to all active caspases (caspase-1, -3, -4, -5, -6, -7, -8
and -9), the cells in the early stages of apoptosis emit red
fluorescence and the intensity of fluorescent light
increases with the advancement in the stage of apoptosis.
Non-apoptotic cells mainly remain unstained (informa-
tion provided by the Immunocytochemistry Technolo-
gies, LLC, Bloomington, MN). We did not separate the cell
populations exhibiting different intensities of fluores-
cence to analyse the percentage of cells in early or late
stage of apoptosis. The measurement of overall fluores-
cence intensity in cells, using fluorometry, suggests that
low dose treatment with rotenone does not induce accel-
erated cell death signals in human microglial cells; at the
end of week four, there was no significant difference in the
levels of active caspases between rotenone treated CHME-
5 cells and the controls (Figure 4). The microscopic obser-
vations suggested that cells in both treatment groups were
fluorescing red with similar intensity (data not shown)
indicating activation of some caspases at reduced levels.
SH-SY5Y cells were used as a positive control for apopto-
sis. The significant increase in the levels of active caspases
in rotenone treated SH-SY5Y cells compared to controls
and rotenone treated CHME-5 cells indicates that the low
dose rotenone treatment does not induce apoptosis in
CHME-5 cells whereas SH-SY5Y cells are more prone to
apoptosis upon rotenone treatment.
SOD1 but not SOD2 increases significantly upon rotenone 
treatment
The main ROS released as a result of mitochondrial
enzyme inhibition is superoxide [22,23,28]. We therefore
analysed the levels of SODs (1 and 2) to determine if
microglia are protected as a result of excessive SOD levels.
In our previous study we reported accumulation of exces-
sive amounts of ROS in SH-SY5Y cells [21]. SH-SY5Y cells
were therefore used as controls in most of these experi-
ments. Interestingly, the basal level of both cytoplasmic
SOD1 and mitochondrial SOD2 were higher (1.6 fold) in
dopaminergic SH-SY5Y cells compared to microglial
CHME-5 cells (Figure 5A and 5B respectively). SOD1 lev-
els increased significantly in microglial cells upon roten-
one treatment at the end of 4 weeks to around 2 fold
(Figure 5A) and no change was observed in SOD2 levels
(Figure 5B). The increase in SOD 1 level was more dra-
matic (2.4 fold) in SH-SY5Y cells upon rotenone treat-
ment for 4 weeks (Figure 5A). These cells also showed
around 1.5 fold increase in SOD2 levels compared to con-
trols, however this increase was not significant (Figure
5B).
Discussion
Exposure to environmental toxins is considered to be a
significant contributor to the pathogenesis of PD. Since
the first report by Betarbet et al. in 2000 [12] that chronic
treatment with the herbicide rotenone leads to selective
destruction of nigrostriatal dopaminergic neurons in
rodents, rotenone has been used widely for establishing
in-vivo and in-vitro models of PD. We and others have also
shown that chronic, low dose treatment of human
dopaminergic neuroblastoma SH-SY5Y cells induces α-
synuclein positive intraneuronal inclusion bodies
[15,21]. Rotenone-induced dopaminergic neurodegener-
ation is attributed to both the mitochondrial impairment
within neurons and enhancement of microglial activation
[22]. Using transgenic mice and primary mesencephalic
cultures, researchers have shown that activated microglia
greatly enhance the rotenone induced neurotoxicity
through the production of pro-inflammatory cytokines
and NADPH oxidase derived superoxide [22,23]. The
effect of rotenone on dopaminergic neurons and the con-
tribution of microglia to neuronal death have been exten-
sively studied. There is however little information
available on the effect of rotenone treatment on microglia
although some researchers have reported microglial acti-
vation upon exposure to rotenone in microglia of animal
origin using rodent in-vivo models and primary mesen-
cephalic cultures [2,12,29]. There are some differences
between microglia of animal and human origin especially
in the way they produce the superoxide anion and iNOS
(inducible nitric oxide synthase) in response to the same
activating agent [24,25]. Therefore, it is important to
determine the effect of rotenone on microglia of human
origin. Due to limited availability of human tissue, low
yield of pure human microglial cultures and ethical issues
on the use of human tissue, we used the transformed
human microglial cell line (CHME-5). To the best of our
knowledge this is the first study investigating the effect of
chronic low dose treatment of rotenone on human micro-
glial (CHME-5) cells.
In the present study we have shown that human microglia
are activated in response to treatment with rotenone; this
was in agreement with other studies using animal models
[2,12,22,23]. Interestingly, and in contrast to dopaminer-
gic SH-SY5Y cells, CHME-5 cells do not show the forma-
tion of inclusions/aggregates at the end of week 4. The
presence/absence of inclusion bodies was confirmed
using both H & E staining to identify any eosinophilic
aggregates and immunocytochemistry to detect any α-
synuclein and ubiquitin positive aggregates. FLICA assay
detects apoptosis in the very early stages if cells are com-
mitted to cell death. We did not find any difference in the
level of apoptosis between rotenone treated and untreated
CHME-5 cells in contrast to the levels of apoptosis in SH-
SY5Y cells suggesting an increased level of tolerance in theMolecular Neurodegeneration 2009, 4:55 http://www.molecularneurodegeneration.com/content/4/1/55
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CHME-5 cells for chronic low dose rotenone. The main
components identified in the inclusion bodies include α-
synuclein and ubiquitin [12,16,21]. Although microglia
have been shown to express both α-synuclein [30] and
ubiquitin [31], the results of this study indicated that
microglia do not form intracellular α-synuclein and ubiq-
uitin positive, eosinophilic protein aggregates, and are
resistant to apoptosis and damage induced by rotenone.
Understanding the mechanisms by which microglia are
protected from the toxic effects of rotenone as well as
pathways/factors by which microglia accelerate neuronal
death is the next important step.
Studies have shown that rotenone treatment induces
mitochondrial impairment leading to excessive genera-
tion and accumulation of ROS (Reactive Oxygen Species)
[12,15,21,32] and that intracellular ROS can accelerate
protein cross-linking within cells [21,29]. We have previ-
ously shown a 48% increase in the intracellular ROS in
SH-SY5Y cells within one week of treatment with roten-
one [21]. These cells showed protein aggregates and intra-
cellular inclusions within four weeks, with the
accumulation of ROS preceding the process of inclusion
body formation in these cells [21]. Surprisingly, in the
present study, we did not find any difference in the accu-
mulation of intracellular ROS in rotenone treated CHME-
5 cells compared to controls. An interesting observation of
the present study was that the rotenone treated SH-SY5Y
cells accumulate large amounts of ROS intracellularly and
do not release significant amounts into the extracellular
environment. However rotenone treated CHME-5 cells do
not accumulate substantial amounts of ROS within cells
but release large amounts of ROS into the extracellular
environment (medium). This may well be one of the rea-
sons why these human microglia do not form protein
aggregates, and in addition this release of extracellular
ROS may cause damage to neurons.
The major ROS generated by rotenone treatment is super-
oxide; superoxide dismutase (SOD) is an anti-oxidant and
superoxide scavenger enzyme known to protect cells
against the toxicity of superoxide [33]. There are two types
of SOD: copper/zinc (Cu/Zn) SOD and manganese (Mn)
SOD. Each type of SOD plays a different role in maintaing
the health of cells. Cu/Zn SOD (SOD1) protects the cell's
cytoplasm, while Mn SOD (SOD2) protects mitochondria
from free radical damage [33,34]. We speculated that
there would be a difference in the levels of SODs in the
two types of cells used in this study and that this might be
responsible for the different levels of ROS observed. We
therefore investigated both SOD1 and SOD2 in SH-SY5Y
and CHME-5 cells after treatment with rotenone. Interest-
ingly the basal levels of both SOD1 and SOD2 were
higher in SH-SY5Y cells compared to CHME-5 cells. SOD1
levels in CHME-5 cells increased approximately two fold
upon exposure to rotenone, however the increase in
SOD1 in SH-SY5Y cells was more dramatic. These results
suggested that microglia do not accumulate ROS intracel-
lularly and therefore the increase in SOD1 was significant
but not dramatic. SH-SY5Y cells show abundant amounts
of intracellular accumulation of ROS within cells [21];
therefore there is an increase in both SOD1 and SOD2 in
these cells. However the dramatic increase in SOD1
affords protection against large amounts of intracellular
ROS.
Microglia express genes encoding all components of
phaogocytic and non phagocytic NADPH oxidases
(Noxs); NOX1, P47 phox, P40 phox, P67 phox, NOXO1,
NoxA1 and Rac1 and a transmembrane flavocytochrome
heterodimer consisting of P22 phox  and the gp91phox
(Nox2) catalytic subunit [33,35,36]. Nox2 generates
superoxide ions and both Nox1 and 2 are important in the
generation of cytotoxic nitrite species [37]. Several studies
have reported that activated microglia generate reactive
oxygen and nitrogen species [36,38]. In brains from
Alzhiemers disease patients, cytocolic Nox components
are observed to be markedly translocated to the mem-
branes of microglial cells [39]. In PD brains, Nox2 has
been shown to be increased in microglial cells [40] and in
Detection of active caspases using FLICA assay Figure 4
Detection of active caspases using FLICA assay. His-
togram showing the levels of active caspases in each of the 
treatment groups from the two cell types (CHME-5 and SH-
SY5Y) at the end of week 4. The levels are expressed in fluo-
rescence units/106 cells. P (*P > 0.05) value indicates that 
there was no significant difference in the level of active cas-
pases between the rotenone treated and untreated CHME-5 
cells. Rotenone treated SH-SY5Y cells showed significantly 
increased (**P < 0.001) levels of active caspases (fluores-
cence units) compared to untreated control cells. Each col-
umn represents the mean and standard deviation from three 
independent experiments.Molecular Neurodegeneration 2009, 4:55 http://www.molecularneurodegeneration.com/content/4/1/55
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Central Nervous System (CNS) Nox has been shown to be
predominanatly present in microglial cells when com-
pared to other cell types [41]. Surprisingly we did not
observe the intracellular accumulation of ROS (mainly
superoxide) within microglia. Cheret et al, [35] observed
intracellular accumulation of superoxide only in
Zymosan engulfing microglia and only within phago-
somes. We did not use zymosan or any other agent that
microglia can engulf, so this may explain in part why we
did not see intracellular ROS accumulation. The results
from Cheret et al, [35] and from our study suggest that
ROS accumulate in microglia only when they are engulf-
ing an agent and ROS are generally compartmentalised
within phagosomes.
Some researchers believe that superoxide diffusion
through the phospholipid bilayer is poor and that cyto-
plasmic superoxide anions do not cause neurotoxicity
directly [33,42]. However Gao et al, [22,23] and others
[43] have attributed rotenone induced neurotoxicity to
the release of NADPH oxidase derived superoxide. The
main question that remains is that if superoxide ions do
not diffuse across the microglial membrane, then how do
microglia accelerate rotenone induced neurotoxicity? It
has been suggested that superoxide is converted into
membrane permeable hydrogen peroxide (H2O2) and
other down stream products such as single oxygen species
and very aggressive hydroxyl radicals (OH-); these prod-
ucts are released into the extracellular environment and
can cross the neuronal membranes or can cause direct
neurotoxicity. In our study, we have observed excessive
amounts of ROS in the extracellular culture medium of
the rotenone treated CHME-5 cells. Dopaminergic neu-
rons are inherently prone to oxidative stress due to their
characteristics of accumulation of high amounts of iron
and dopamine [44,45]. In the presence of redox active
iron, highly reactive and toxic hydroxyl radicals (OH-) are
generated from H2O2 and superoxide [46]. Most impor-
tantly, extracellular ROS appear to promote mitochon-
drial generation of intracellular ROS in dopaminergic
cells [47]. Therefore microglia originated superoxide
induced by rotenone might damage dopaminergic neu-
rons directly via formation of membrane permeable
downstream products or may promote neuronal mito-
chondrial ROS production that is a result of complex I
enzyme inhibition.
Different treatments and signalling pathways lead to the
production of either superoxide or nitric oxide (NO)
using Nox or iNOS pathways respectively [33]. Since
human microglia produce little or no iNOS [24,25], the
main pathway in human microglia for superoxide produc-
tion appears to be via Nox. Activation of the Nox system
results in the generation of superoxide within minutes
[36]. While the ROS generated by microglial cells have the
Superoxide dismutase (SOD) levels in both CHME-5 and SH- SY5Y cells Figure 5
Superoxide dismutase (SOD) levels in both CHME-5 
and SH-SY5Y cells. Figure 5A: Representative immunob-
lot and histogram showing levels of SOD1 in the two types of 
cells (CHME-5 and SH-SY5Y) collected from two treatment 
groups (DMSO control and rotenone treated). CHME-5 cells 
showed a significant (p < 0.05) two fold increase in SOD1 
levels, whereas SH-SY5Y cells showed a more significant 2.4 
fold increase (p < 0.01) in SOD1 levels after 4 weeks of 
rotenone treatment. The base levels of SOD1 appeared to 
be higher in SH-SY5Y cells compared to CHME-5 cells. Fig-
ure 5B: Representative immunoblot and histogram showing 
levels of SOD2 in the two types of cells (CHME-5 and SH-
SY5Y) collected from two treatment groups (DMSO control 
and rotenone treated). CHME-5 cells did not show any 
change in SOD2 levels (p > 0.05), whereas SH-SY5Y cells 
showed a 1.5 fold increase in SOD2 levels after 4 weeks of 
rotenone treatment, although this increase was not signifi-
cant (p > 0.05). The base levels of SOD2 appeared to be 
higher in SH-SY5Y cells compared to CHME-5 cells. 1: 
CHME-5 control; 2: CHME-5 rotenone; 3: SH-SY5Y control; 
4: SH-SY5Y rotenone. Each column represents the mean and 
standard deviation from three independent experiments.Molecular Neurodegeneration 2009, 4:55 http://www.molecularneurodegeneration.com/content/4/1/55
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potential to harm the producing cells themselves, these do
not appear to cause substantial damage to microglial cells
[33], suggesting that microglial cells are well equipped
with a strong antioxidative defense mechanisms to protect
against oxidative and nitrosative damage. The first line of
defence against ROS is the small molecular weight com-
ponents such as glutathione, ascorbate and α-tocopherol.
These compounds react easily with radicals [33,48], and
additionally, the antioxidant enzymes such as SODs, cat-
alase, glutathione peroxidase (Gpx) and glutathione
reductase (GR) also play an important role in clearing the
ROS [33]. Microglia have been shown to contain the high-
est levels of glutathione (GSH) compared to astrocytes
and oligodendrocytes in rat brain cell cultures and in the
rat mixed primary cell cultures [49,50]. Depending on the
type of stimulus, the microglial content of GSH can be
increased by increased GSH synthesis or decreased by
increased consumption of GSH [49,51]. In addition, the
presence of several antioxidant enzymes such as SOD1,
GPx, and catalase has been reported in brain sections of
rat and human origin. Interestingly MnSOD (SOD2) was
not detected in unstressed conditions [33,34,52] and per-
oxyredoxin 1, an antioxidant protein was observed only in
activated microglia [53]. It is thought that as soon as
superoxide is produced by Nox, it is quickly converted to
O2 and H2O2 in microglia by SODs. H2O2 reacts with GSH
or with NO to form peroxynitrite. H2O2 and peroxynitirite
are membrane permeable and can directly damage neu-
rons. In addition H2O2 and ROS also facilitate phagocyto-
sis and stimulate expression of microglial Tumour
Necrosis Factor-α (TNF-α) [54]. In relation to anti-oxida-
tive mechanisms, it could be said that microglial cells are
well equipped with a strong GSH system and other anti-
oxidative enzymes and can therefore adapt easily to stress
conditions.
Conclusion
In Conclusion, we have shown that similar to microglia of
animal origin, human microglia (cell line) are activated in
response to chronic low dose rotenone treatment. Human
microglia do not show accumulation of excess amounts of
intracellular ROS, however release abundant amounts of
ROS into the extracellular environment (culture
medium). Chronic low dose rotenone treatment does not
induce accelerated apoptosis in microglia. Although
human dopaminergic SH-SY5Y neurons show excessive
amounts of both SODs, neurons develop eosinophilic
inclusion bodies positive for both α-synuclein and ubiq-
uitin within four weeks of rotenone treatment. The ele-
vated levels of SODs in neurons appear to be in response
to high levels of ROS generated within the neurons them-
selves upon rotenone treatment. Microglia appear to be
'resistant' to rotenone (chronic low dose) induced toxicity
and do not show protein aggregation or inclusion body
formation. Although the mechanism of microglial
defence/resistance against rotenone toxicity can be
explained in part by our results and the available current
literature, further in depth studies need to be undertaken
to fully explain this resilience.
Methods
Cell Culture and Rotenone Treatment
We used the transformed human microglial cell line
CHME-5 in this study. The availability of human tissue,
low yield of human microglia and ethical issues associ-
ated with the use of the human tissue pose significant
challenges for establishing primary human microglia.
CHME-5 (a generous gift from Professor Pierre Talbot,
Laboratory of Neuroimmunovirology, INRS-Institute,
Armand-Frappier, Canada) was obtained from embryonic
fetal human microglia through transformation with SV-40
virus [55,56]. This cell line has been well characterized by
Prof Talbot's group and others [55-57]. These cells express
the antigens present on the adult human microglia,
secrete the pro-inflammatory cytokines upon activation,
exhibit the properties of primary human microglia and
have been successfully used as a model for microglial acti-
vation by others [55,57,58]. Cells (1.7 × 102 cells/25 cm2)
were grown in complete DMEM-F12 (Dulbecco's Modi-
fied Eagle Medium-F12) medium with 10% FBS (Fetal
Bovine Serum), 2 mM glutamine and 1 mM sodium pyru-
vate at 37°C under 5% CO2 in air. Media were supple-
mented with 5 nM rotenone (Sigma Aldrich, USA) or with
solvent (DMSO, used to dissolve rotenone) for 4 weeks.
The concentration of rotenone was based on our previous
work [21] where we have shown that treatment of human
dopaminergic cells (SH-SY5Y) with 5 nM rotenone results
in the appearance of intracellular inclusion bodies in
these cells within four weeks. Cells were grown in 100 mm
plates and fed twice weekly with the respective/appropri-
ate media. Cultures were passaged on reaching conflu-
ence. Cover slips of a 12 mm diameter were placed in each
plate. Three/four coverslips were retrieved from each treat-
ment group at the end of every week. Cells on coverslips,
collected for immunocytochemical assays, were fixed
immediately in 4% buffered paraformaldehyde for 15-20
min, washed with PBS and stored in PBS with 0.1%
sodium azide at 4°C until further use. Cells and cell
lysates collected at the end of week 4 were used for immu-
nocytochemical (for α-synuclein, ubiquitin and CR/43
proteins), biochemical (FLICA-apoptosis assay and DHE-
ROS assay), Haematoxylin-Eosin (H & E) staining of cells
and western blot assays (for Glut-5 and SODs levels).
Extracellular ROS released by cells into the culture media
were measured at week 4 using Acridan Lumigen PS-3
assay.
Detection of intracellular inclusion bodies by H & E and 
Immunofluorescent staining
a. Haematoxylin-Eosin (H & E) staining
To confirm the presence/absence of inclusion bodies in
the CHME-5 cells, cells grown on coverslips and parafor-Molecular Neurodegeneration 2009, 4:55 http://www.molecularneurodegeneration.com/content/4/1/55
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maldehyde (PFA) fixed were stained with H & E using a
standard protocol. Briefly, cells were incubated with 2%
Gill's Haematoxylin solution for 5 minutes, rinsed with
distilled water followed by 10 dips (30 sec each) in blue-
ing Solution (supernatant of the saturated solution of
Lithium chloride), washed with water for 5 minutes, then
the cells were incubated in 1% Eosin solution for 2 min-
utes. Coverslips were mounted using Aquatex mount
(Merck, Germany) after the final rinse in water. Inclusion
bodies, known to be eosinophilic, were identified using a
Leica DMR upright light microscope.
b. Immunofluorescent staining
α-synuclein and ubiquitin are main components of the
lewy inclusion bodies within neurons; microglia also
express α-synuclein [30] and ubiquitin [31]. These two
proteins were therefore used as markers to monitor the
development of intracellular inclusion bodies within
microglial cells. Cells grown on cover slips were processed
for the detection of α-synuclein positive inclusion bodies
as previously described [21]. Briefly, cells collected at
week 4 were processed for the detection of α-synuclein
using immunofluorescent (immunocytochemical) tech-
niques. The coverslips were placed in 24 well plates, cells
were blocked for non-specific reactivity by incubating
cells/coverslips with 20% normal goat serum in PBS-T for
2 hrs, washed three times with PBS and then incubated
with rabbit anti-human α-synuclein (Chemicon Interna-
tional Inc, USA; 1:500 diluted in the blocking solution)
for 3 hrs followed by 2 hrs incubation with anti-rabbit
Alexa 568 (red; Molecular Probes, USA) secondary anti-
body at 1:400 dilution in the blocking solution. For ubiq-
uitin staining, cells were blocked with 10% normal goat
serum in PBS-T for 2 hrs, followed by incubation with rab-
bit anti-ubiquitin antibody (Dako, USA, 1:1000 diluted in
the blocking solution) for 3 hrs and anti-rabbit Alexa 488
secondary antibody (green; Molecular Probes, USA, 1:500
diluted in the blocking solution). Hoechst 33258 (Molec-
ular Probes, USA) was used to stain the cell nucleus. Cov-
erslips were mounted using prolong gold mounting
medium (Molecular Probes, USA). Images were recorded
using a Leica DMR fluorescent microscope.
Since we have already shown that rotenone treatment
induces inclusion body formation in SH-SY5Y human
dopaminergic cells within 4 weeks [21], we used these
cells as a positive control for inclusion body formation in
CHME-5 cells. These cells were treated similarly as
described previously [21] before being processed for H &
E, α-synuclein and ubiquitin staining using the specific
antibodies described above.
Detection of ROS (Reactive Oxygen Species)
a. Intracellular ROS
ROS (mainly superoxide) generated within the cells were
detected using dihydroethidium (DHE; Molecular Probes,
Invitrogen, USA) as described previously [21]. DHE is a
cell permeable fluorescent dye that is oxidized by ROS
present in the cytoplasm, and in an oxidized state, interca-
lates with nuclear DNA and is detectable as red fluores-
cence [21,59]. The extent of DHE fluorescence
corresponds to the amount of ROS present in cells. Both
cell types (CHME-5 and SH-SY5Y) cultured on coverslips
from two treatment groups as described above (DMSO
control and 5 nM rotenone) were collected in 24 well
plates at the end of week 4 (28 days), the cells incubated
with 5 μM DHE (diluted in the respective media) at 37°C
for 30 minutes. After incubation, cells were washed in PBS
and fixed in 4% buffered paraformaldehyde for 10 min-
utes, washed with PBS and treated with Hoechst 33258
nuclear dye (Molecular Probes, Invitrogen, USA; 1:500
diluted in PBS) for 5 minutes. Cells were washed again
with PBS and coverslips mounted with Prolong gold
mounting medium (Molecular Probes, USA). All images
(2560 × 1920 pixels) were collected at the same camera
settings using a Leica DMR Fluorescent microscope. DHE
fluorescence was analyzed using Image J software. Since
the area of interest was the nucleus of each cell, a bound-
ary was drawn around each nucleus (using RGB images)
and the marked areas saved in ROI (Region of Interest)
manager. The ROI were opened as grey scale images and
the mean fluorescence intensity of pixels (mean grey
value) within the nuclear boundaries determined for all
the images. 50 cells/treatment group/cell type were used
for ROS measurements.
b. Extracellular ROS
ROS released into the medium by the cells were measured
in the culture media collected at the end of the week 4
using the Acridan Lumigen PS-3 assay (developed in our
laboratory) using a 96 well plate format. Acridan com-
pounds (or acridinium derivatives) can be oxidised enzy-
matically or electrochemically; in both cases oxidation
products generate chemiluminescence [60,61]. Acridan
compounds are therefore widely used as a chemilumines-
cent substrate for the detection of bands using enzymatic
oxidation in a western blot method. We used Acridan
Lumigen PS-3, provided by GE Healthcare (UK), as a
chemiluminescent substrate for HRP (Horse Radish Per-
oxidase) in the ECL plus kit. Lumigen PS-3 reacts with
hydrogen peroxide and forms acridinium esters that can
be oxidised with free radicals and excited products emit
light at 430 nm. For the purpose of measuring ROS in the
culture media, we mixed Reagent A (H2O2, ECL plus kit,
GE Healthcare, UK) and Reagent B (Acridan substrate,
ECL plus kit, GE Healthcare, UK) as per the manufac-
turer's instructions (in 40:1 ratio); this mixture was
named the PS-3 substrate. 50 μl of each sample from three
different replicates were plated in a 96 well plate, 50 μl of
TBS (Tris Buffered Saline) was added into each well fol-
lowed by 50 μl of the PS-3 substrate. The plate was incu-
bated in the dark for 2 minutes at room temperature.Molecular Neurodegeneration 2009, 4:55 http://www.molecularneurodegeneration.com/content/4/1/55
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Chemiluminescence was recorded digitally using Fujifilm
Luminescent Image Analyzer (LAS-1000, Version 1.0.0).
The Light intensity (photons) was also measured using
BioTek Synergy 2 plate reader and Gen5 software. The
readings recorded by the Biotek plate reader were used for
analysis. The specificity of the Acridan PS-3 assay in gen-
erating ROS specific chemiluminescence was confirmed
in this study by using two different antioxidants. The cul-
ture media collected from rotenone treated CHME-5 cells
at the end of week 4 were incubated with either 100 μM
ascorbic acid (vitamin C, antioxidant) or 1:500 diluted
NuPAGE antioxidant (Invitrogen) containing Sodium
bisulfite, a strong antioxidant against a wide range of ROS
including superoxide anions [62]. The dose of antioxi-
dants was decided by performing pilot dose response
experiments with these antioxidants (data not shown).
The incubation of the media with these antioxidants was
carried out for 5 minutes before adding the PS-3 substrate;
chemiluminescence was recorded as described above.
Detection of early signs of apoptosis using FLICA apoptosis 
kit
Apoptosis/programmed cell death is a multi-step process
[63]. These stages include an initiation stage - cell obtains
the initial cell death activation signals; a commitment stage
- the cell becomes committed to apoptosis; an amplifica-
tion stage: multiple caspases are activated, and a demolition
stage - caspase mediated destruction of the cellular struc-
ture. The FLICA (Fluorochrome Inhibitor of Caspases)
apoptosis detection kit is designed to detect active cas-
pases. The Fluorochrome inhibitor (SR-VAD-FMK, Sul-
forhodaminyl-L-valylalanylaspartyl fluoromethyl ketone)
used in this assay is cell permeable and non cytotoxic, and
once in the cell, binds covalently to all active caspases.
Covalently bound inhibitors are retained in the cell while
any unbound reagent is washed away. Thus the remaining
cell fluorescent signal is a direct measure of the amount of
active caspase enzymes present at the time the reagent was
added. The cells can be analysed by 96 well plate fluorom-
etry or by fluorescence microscopy. For this study, the
cells (both CHME-5 and SH-SY5Y) were collected at the
end of 28 days (week 4) and FLICA assay was performed
on the trypsinised cells suspended in 96 well plates,
according to the manufacturer's instructions (Immunocy-
tochemistry Technologies, LLC, Bloomington, MN). The
amount of caspases was analysed by recording the fluores-
cent signals in the 96 well plate using Biotek Synergy 2
plate reader and Gen5 software.
Detection of microglial activation and levels of SODs using 
immunocytochemical and western blotting methods
a. Glucose transporter type 5 and CR3/43
Glucose transporter type 5 (Glut-5) is a microglia specific
protein [27,64], that contributes to the kinetics of cerebral
metabolism. The expression of Glut-5 is detected at all
stages of microglial activation, however its expression
increases with activation [26]. We therefore used Glut-5 as
the marker for microglial activation. The levels of Glut-5
were measured using Western blot methods and the poly-
clonal Rabbit-anti-humanGlut-5 antibody (Chemicon
International Inc, USA). Briefly, 15 μg of each sample was
loaded into separate wells of a 4-12% gradient SDS PAGE
gel (NuPAGE, Invitrogen) and run at 200 V. A nitrocellu-
lose membrane and MOPS transfer buffer (with 10%
methanol) were used for transfer at 30 V for 1 hr at 4°C.
The membrane was blocked with 5% non fat milk in PBS-
T (PBS with 0.1% Tween 20) for 16-18 hrs at 4°C. After
blocking, the membrane was washed three times in PBS-T
at room temperature (RT) followed by incubation for 3
hrs at RT with the primary antibody at 1:500 diluted in 1%
milk in PBS-T. The membrane was then washed twice with
PBS-T, followed by incubation with anti-rabbit-HRP con-
jugated secondary antibody (Sigma Aldrich, USA; 1:
16000 diluted in 1% milk in PBS-T). Chemiluminescent
signals were captured using an ECL-plus chemilumines-
cent kit (GE Healthcare, UK) and Fujifilm Luminescent
Image Analyzer (LAS-1000, Version 1.0.0).
Microglial activation was also confirmed using CR3/43 as
a marker and immunocytochemical method. CR3/43 also
known as HLA DR/DP/DQ belongs to the family of
Human Leukocyte Antigens (HLA) with important roles
in the immune system. CR3/43 protein is specifically
expressed in activated microglia and is therefore used as a
marker for activated microglia [65,66]. To confirm the
activated state of microglia, the cells grown on colverslips
were fixed in 4% buffered paraformaldehyde, washed
with PBS and processed for the detection of CR3/43 pro-
tein at the end of the week 4 using the monoclonal CR3/
43 antibody (abcam, UK, 1:100 diluted in the blocking
solution) and respective secondary antibody (Alexa 488
conjugated, 1: 400 diluted, Molecular Probes). Cells were
washed three times with PBS-T (PBS having 0.1% Tween
20) after primary and secondary antibody incubations.
Following secondary antibody washes, cells were treated
with Hoechst 33258 nuclear dye (Molecular Probes, Inv-
itrogen, USA; 1:500 diluted in PBS) for 5 minutes, washed
with PBS and coverslips mounted with Prolong gold
mounting medium (Molecular Probes, USA). Images
(2560 × 1920 pixels) were recorded using a Leica DMR
Fluorescent microscope.
b. Superoxide dismutases (SODs)
SOD 1 and 2 were used to assess the ability of microglia
to 'defend' against the accumulation/generation of Reac-
tive Oxygen Species (ROS). Polyclonal anti-rabbit anti-
bodies for SOD1 (abcam, UK) and SOD2 (gift from
Professor Mike Berridge, Malaghan Institute of Medical
Research, Victoria University, Wellington, New Zealand)
were used.Molecular Neurodegeneration 2009, 4:55 http://www.molecularneurodegeneration.com/content/4/1/55
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The levels of SOD 1 and 2 were measured using western
blot methods as described above for Glut-5 levels; the
concentrations of primary antibodies were 1: 5000 and
1:1000 for SOD 1 and 2 respectively. Anti-rabbit second-
ary antibody was used at 1:16,000 dilution for both the
targets. Chemiluminescent signals were recorded using an
ECL-plus chemiluminescent kit (GE Healthcare, UK) and
Fujifilm Luminescent Image Analyzer (LAS-1000, Version
1.0.0).
Statistical analysis
Each experiment described above was repeated three
times and data from three independent experiments used
for statistical analysis. Differences between the two groups
were compared using a Student's t test (Prism software,
version 3.02, GrapPad Inc, USA) with P < 0.05 considered
a significant difference. Results shown are representative
of three independent experiments. All data were expressed
as the mean ± standard deviation.
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